DeepCure: AI Path from 10^18 Compounds to Preclinical Data
DeepCure narrows a vast chemical space to candidates via AI, then validates them in models and tissue—not yet patients.
- Search & design: Generative...

Created by Christine Farley
AI-driven biotech breakthroughs, explainers, and learning resources for drug discovery, genomics, imaging
Explore the latest content tracked by AI BioInsights Hub
DeepCure narrows a vast chemical space to candidates via AI, then validates them in models and tissue—not yet patients.
Recent advances in artificial intelligence, including deep learning, genomic language models, and transformer-based architectures, are redefining multiomics integration for cancer through interpretable AI.
A recent review outlines a clear taxonomy for combining biological mechanisms with AI in drug discovery and genomics.
AI-as-intervention is defined as AI whose output itself becomes part of the assigned clinical intervention under evaluation. This framing shows why precise trial design and evidence standards are essential to isolate AI's true impact.
Seven ML techniques address heart-disease prediction from clinical data, while five pre-trained models target CT scans per the paper's scope;...
AI now predicts protein structures, suggests enzyme changes, and maps biological pathways in days instead of months. This links computational design...
The insitro-AstraZeneca collaboration highlights how human and cellular data can guide target selection for heterogeneous diseases like MASH and...
The seminar titled “Is Structure Based Drug Design and Toxicology Ready for Ion Channels and Transporters?” directly examines the readiness of these AI-enabled methods for this challenging protein class.
Can AI screening improve clinical-trial enrollment?
AI is emerging as the latest scientific tool, much like past advances from test tubes to computing, with examples including AlphaFold’s 200m protein...
Enrollment rarely follows initial assumptions as site activation delays and recruitment rates shift over time.
AI-driven molecular generation and structure-based drug discovery are reshaping design processes, yet they raise security questions as tools reach...
站点级入组数据揭示患者需求轨迹,可在总体里程碑前更新需求预测。
贝叶斯模型实时调整站点招募率,转化为未来就诊、剂量和试剂需求模拟。
库存策略用预测百分位触发补货,平衡缺货与过期成本。
校准预测区间比平均值更关键,可避免低估上尾导致的库存短缺。
Traditional AIDD acts as a research assistant for molecule generation, property prediction, and candidate prioritization based on datasets.
Agentic...
传统Phase 1需剂量探索、3+3设计或停止规则,该AI试验均缺失。
AI框架已能演化基因编辑蛋白、设计分子架构并生成全新酶,把CRISPR从基础工具扩展为优化平台。
AI与生物信息学结合需要生物学知识、编程、数据分析和AI/ML技能,但应从生物问题出发应用AI。
The cloud-based drug discovery platforms market is forecast to surge from USD 4.2 billion to USD 11.4 billion by 2035 at an 11.7% CAGR, fueled by AI...
Repeatable clinical outcomes and experimental validation—not faster predictions alone—will decide AI drug discovery's lasting impact. Insilico's 33...